Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27 2024 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on in-licensing,
developing, and commercializing novel medicines for patients living
with rare and difficult-to-treat diseases, today announced that
Richard J. Daly, CEO of Catalyst, along with other members of
Catalyst’s management team, will participate in the 2024
Cantor Virtual Muscular Dystrophy Symposium taking place virtually
on April 2-3, 2024.
Presentation Details: |
Event: |
Cantor Virtual
Muscular Dystrophy Symposium |
Date: |
April 2, 2024 |
Time: |
3:10 PM ET |
|
|
The presentation webcast will be available on
the Investors section of the Company's website, and a replay
will be accessible for at least 14 days.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare and difficult-to-treat
diseases. Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment
of Lambert-Eaton myasthenic syndrome ("LEMS") for adults
and for children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights to FYCOMPA®
(perampanel) CIII, a prescription medicine approved in people with
epilepsy aged four and older alone or with other medicines to treat
partial-onset seizures with or without secondarily generalized
seizures and with other medicines to treat primary generalized
tonic-clonic seizures for people with epilepsy aged 12 and older.
Further, Canada's national healthcare regulatory
agency, Health Canada, has approved the use of FIRDAPSE for
the treatment of adult patients in Canada with LEMS.
Finally, on July 18, 2023, Catalyst acquired an exclusive
license for North America for AGAMREE® (vamorolone) oral
suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne
Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26, 2023.
AGAMREE became commercially available by prescription in the U.S.
on March 13, 2024.
For more information about Catalyst
Pharmaceuticals, Inc., please visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, please visit www.firdapse.com. For
Full Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE®, please visit www.agamree.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including those factors described in Catalyst's Annual
Report on Form 10-K for the fiscal year 2023 and its other filings
with the U.S. Securities and Exchange Commission ("SEC"),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Relations Contact:
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact:
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2023 to Aug 2024